Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Wainberg

Showing results (61-70 of 341) with videos related to

Pageof 35
Sort By:
Viruses|October 14, 2011
Role of HIV Subtype Diversity in the Development of Resistance to Antiviral DrugsMark A Wainberg, Bluma G Brenner
Retrovirology|November 17, 2016
HIV and Zika: When will we be able to end these epidemics?Mark A Wainberg, Andrew M L Lever
The Journal of Antimicrobial Chemotherapy|December 3, 2003
Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1Dan Turner, Bluma Brenner, Mark A Wainberg
AIDS (London, England)|August 2, 2013
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventionsBluma Brenner, Mark A Wainberg, Michel Roger
Journal of the International AIDS Society|November 19, 2008
Journal of the International AIDS Society: an important step forwardMark A Wainberg, Elly Katabira, Shirin Heidari
Retrovirology|December 5, 2014
How will the ebola crisis impact the HIV epidemic?Mark A Wainberg, Andrew M L Lever
Antiviral Research|June 22, 2006
Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?Jorge Martinez, Paul Coplan, Mark A Wainberg
Virus Research|September 21, 2010
Structural changes in the SL5 and SL6 leader sequences of HIV-1 RNA following interactions with the viral mGag proteinAriel Roldan, Chen Liang, Mark A Wainberg
The Journal of Antimicrobial Chemotherapy|August 22, 2013
Defective HIV-1 quasispecies in the form of multiply drug-resistant proviral DNA within cells can be rescued by superinfection with different subtype variants of HIV-1 and by HIV-2 and SIVYudong Quan, Hongtao Xu, Mark A Wainberg
BMC Medicine|November 26, 2013
What if HIV were unable to develop resistance against a new therapeutic agent?Mark A Wainberg, Thibault Mesplède, Francois Raffi
Pageof 35

Showing results (61-70 of 341) with videos related to

Sort By:
Pageof 35
Viruses|October 14, 2011
Role of HIV Subtype Diversity in the Development of Resistance to Antiviral DrugsMark A Wainberg, Bluma G Brenner
Retrovirology|November 17, 2016
HIV and Zika: When will we be able to end these epidemics?Mark A Wainberg, Andrew M L Lever
The Journal of Antimicrobial Chemotherapy|December 3, 2003
Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1Dan Turner, Bluma Brenner, Mark A Wainberg
AIDS (London, England)|August 2, 2013
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventionsBluma Brenner, Mark A Wainberg, Michel Roger
Journal of the International AIDS Society|November 19, 2008
Journal of the International AIDS Society: an important step forwardMark A Wainberg, Elly Katabira, Shirin Heidari
Retrovirology|December 5, 2014
How will the ebola crisis impact the HIV epidemic?Mark A Wainberg, Andrew M L Lever
Antiviral Research|June 22, 2006
Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?Jorge Martinez, Paul Coplan, Mark A Wainberg
Virus Research|September 21, 2010
Structural changes in the SL5 and SL6 leader sequences of HIV-1 RNA following interactions with the viral mGag proteinAriel Roldan, Chen Liang, Mark A Wainberg
The Journal of Antimicrobial Chemotherapy|August 22, 2013
Defective HIV-1 quasispecies in the form of multiply drug-resistant proviral DNA within cells can be rescued by superinfection with different subtype variants of HIV-1 and by HIV-2 and SIVYudong Quan, Hongtao Xu, Mark A Wainberg
BMC Medicine|November 26, 2013
What if HIV were unable to develop resistance against a new therapeutic agent?Mark A Wainberg, Thibault Mesplède, Francois Raffi
Pageof 35